MX2024004762A - Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r. - Google Patents

Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.

Info

Publication number
MX2024004762A
MX2024004762A MX2024004762A MX2024004762A MX2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A
Authority
MX
Mexico
Prior art keywords
methods
antagonist
administering
prurigo nodularis
treating
Prior art date
Application number
MX2024004762A
Other languages
English (en)
Spanish (es)
Inventor
Ashish Bansal
Heribert Staudinger
Elizabeth Laws
Naimish Patel
John O''MALLEY
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2024004762A publication Critical patent/MX2024004762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024004762A 2021-10-20 2022-10-19 Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r. MX2024004762A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163257876P 2021-10-20 2021-10-20
US202263300492P 2022-01-18 2022-01-18
EP22315048 2022-03-04
PCT/US2022/078341 WO2023069976A1 (en) 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
MX2024004762A true MX2024004762A (es) 2024-05-08

Family

ID=84329583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004762A MX2024004762A (es) 2021-10-20 2022-10-19 Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.

Country Status (10)

Country Link
US (1) US20230183362A1 (cg-RX-API-DMAC10.html)
EP (1) EP4419557A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539148A (cg-RX-API-DMAC10.html)
KR (1) KR20240099290A (cg-RX-API-DMAC10.html)
CN (1) CN119137149A (cg-RX-API-DMAC10.html)
AU (1) AU2022369296A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235380A1 (cg-RX-API-DMAC10.html)
IL (1) IL312187A (cg-RX-API-DMAC10.html)
MX (1) MX2024004762A (cg-RX-API-DMAC10.html)
WO (1) WO2023069976A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CA3161037A1 (en) * 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
WO2022052974A1 (en) 2020-09-10 2022-03-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof

Also Published As

Publication number Publication date
AU2022369296A1 (en) 2024-05-30
US20230183362A1 (en) 2023-06-15
KR20240099290A (ko) 2024-06-28
CN119137149A (zh) 2024-12-13
CA3235380A1 (en) 2023-04-27
WO2023069976A1 (en) 2023-04-27
IL312187A (en) 2024-06-01
EP4419557A1 (en) 2024-08-28
JP2024539148A (ja) 2024-10-28

Similar Documents

Publication Publication Date Title
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
MX2022014440A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
MX387530B (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña.
MX2022011730A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
MX2024010244A (es) Uso de un inhibidor del receptor de interleucina-4 (il-4r) para tratar la dermatitis atopica.
MY163953A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2022001030A (es) Metodos para tratar alergia y mejorar la inmunoterapia especifica de alergenos mediante la administracion de un antagonista de il-4r.
MX2025011152A (es) Metodos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc) mediante la administracion de un antagonista de il-4r
EA201590210A1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
PH12013500890A1 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
MX2023007945A (es) Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
MX2025005113A (es) Metodos para tratar la dermatitis de manos y pies mediante la administracion de un antagonista de il-4r
PH12021551739A1 (en) Methods of treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 (rantes) interaction, and compositions for practicing the same
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
IL312187A (en) Methods for treating prurigo nodularis by administering an IL-4R antagonist
MX2024002072A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX2023001199A (es) Antagonistas de receptor nk para pacientes con cancer.